APIS & the Pharmaceutical Value Chain
The pharmaceutical value chain
APIs are produced according to Good Manufacturing Practices (GMP) defined by regulatory authorities. The entire system is controlled by very strict regulatory procedures.
APIS ad pharmaceutical excipients are essential in the development of pharmaceuticals and together they deliver the curative effect of formulated medicines.
To build a resilient pharmaceutical supply chain, we need a coherent European pharmaceutical strategy to:
Restore and secure the production of the critical and strategic pharmaceutical components in Europe
Support investments to boost innovation, ensure European industry’s competitiveness globally, whilst maintaining high quality, safety and environmental standards
Ensure regulatory flexibility (e.g. fast track approvals during crises and emergencies), to endorse new technologies and prevent future shortages due to unforeseen events or surges in demand
Coordinate at European level a list of essential medicines that need to be available at all times and monitor any risks of spikes or shortages
Our member companies in Europe have production facilities, critical know-how, R&D integrated structures and advanced technology, as well as a highly skilled manpower. They operate according to the highest regulatory, quality and environmental standards.
We work relentlessly towards our goal of ensuring the safe supply of high-quality medicines for every patient in Europe and building a resilient and sustainable European pharmaceutical supply chain.
Producing a single API
is a complex process requiring many steps and raw materials
Intermediate
Raw Material
Regulatory Starting Material